OTSUKA

Otsuka Beijing Research Institute (OBRI) (Otsuka Beijing Research Institute, referred to as OBRI) is a wholly-owned Japanese pharmaceutical R&D enterprise established in Beijing in August 2003, invested by Otsuka Pharmaceutical Co., Ltd. of Japan. Mainly engaged in the research and development of clinical medicine, pharmaceutical raw materials, pharmaceutical preparations, biochemical and biological engineering products, medical equipment and other products; transfer of own technology; technical development, technical consultation, and technical services in medical products. Japan’s Otsuka Pharmaceutical Co., Ltd. is an internationally renowned large-scale comprehensive enterprise with a history of nearly a hundred years, integrating R&D, production and sales of medicines, health products, health foods, and medical test reagents. As early as 1981, Mr. Masaji Otsuka and Mr. Akihiko Otsuka, the founders of Otsuka Pharmaceuticals, cooperated with China National Pharmaceutical Investment Co., Ltd., a subsidiary of China National Pharmaceutical Group Co., Ltd., and successfully established China’s first Sino-foreign joint pharmaceutical company in Tianjin-China Otsuka Pharmaceutical Co., Ltd., which is also the first joint venture pharmaceutical company between China and Japan, has introduced foreign capital for China’s reform and opening up, especially in the introduction of advanced corporate management models and Good Manufacturing Practices (GMP), etc. In this regard, he has made courageous and positive contributions and has been respected and praised by the industry. Over the past 30 years, Otsuka Pharmaceutical has continued to increase its investment in China, and has successively established more than 20 wholly-owned and joint ventures in Guangdong, Sichuan, Shanghai, Tianjin, Suzhou, Dalian and other places. One of the Japanese-funded enterprises with high social influence and wide coverage.